Bliss GVS Pharma Announces Re. 0.50 Interim Dividend for FY2025-26, Sets Feb 18 Record Date
Bliss GVS Pharma declared an interim dividend of Re. 0.50 per equity share for FY2025-26. The record date for this dividend is February 18, 2026. Tax will be deducted at source as per Income Tax Act provisions. Shareholders must submit relevant tax documents by February 23, 2026.
The announcement pertains to a standard interim dividend payment with detailed tax information. The dividend amount is nominal (Re. 0.50 per share), and the primary focus is on tax compliance procedures, which typically have a low direct impact on the company's stock price.
The announcement is a routine declaration of an interim dividend and provides detailed information on tax implications. While a dividend is generally positive, the core of the announcement focuses on tax compliance and procedures, making the sentiment neutral.
Bliss GVS Pharma Limited has announced an interim dividend of Re. 0.50 per equity share for the financial year 2025-2026. The Board of Directors declared this dividend at a meeting held on February 10, 2026. The dividend will be payable within 30 days of declaration. The company has fixed Wednesday, February 18, 2026, as the record date for determining the eligibility of shareholders to receive this interim dividend.
As per the Income Tax Act, 1961, dividends paid or distributed after April 1, 2020, are taxable in the hands of shareholders. Consequently, Bliss GVS Pharma will be required to deduct tax at source (TDS) at the time of dividend payment. The communication details the applicable TDS provisions for both resident and non-resident shareholders, including rates, documentation requirements, and procedures for claiming tax exemptions or lower withholding tax, referencing various sections of the Income Tax Act and relevant forms like 15G and 15H.
The company has also provided information on updating bank account details for direct dividend credit and emphasizes the importance of submitting necessary tax-related documents by February 23, 2026, to ensure correct TDS deduction. Shareholders are advised to consult their tax advisors for specific guidance.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.